



7 June 2023  
EMA/899164/2022  
Human Medicines Division

## Abbreviations used in EMA human medicines scientific committees & CMDh documents and in relation to EMA's regulatory activities

Abbreviation <sup>1</sup>	
AA	Accelerated Assessment
ACT EU initiative	Accelerate Clinical Trials in the EU (see <a href="#">ACT EU</a> )
ADR(s)	Adverse Drug Reaction(s) (see <a href="#">GVP</a> annex I)
AE(s)	Adverse Event(s) (see <a href="#">GVP</a> annex I)
AEFI(s)	Adverse Event(s) Following Immunisation (see <a href="#">GVP</a> annex I)
AESI	Adverse Event of Special Interest
AHEG	(EMA) Ad Hoc Expert Group
AI	Artificial Intelligence
AM	Additional Monitoring
AMR	Antimicrobial resistance (see <a href="#">Antimicrobial resistance</a> )
ANVISA	Brazilian health regulatory agency (see <a href="#">International agreements</a> )
API	Active Pharmaceutical Ingredient (see <a href="#">International collaboration on GMP inspections</a> )
AR(s)	Assessment Report(s)
ARSP	Assessment Report Summary for the Public (see <a href="#">EU herbal monographs</a> )
ASMF WG	(Joint EMA/HMA) Active Substance Master File Working Group (see <a href="#">ASMF WG</a> )
ATC(/DDD)	Anatomical Therapeutic Chemical classification system, maintained by WHO (with Defined Daily Doses)
ATD	(EMA) Access to Documents (see <a href="#">Access to documents</a> )
ATD	Anti-Tampering Device (see <a href="#">Falsified medicines: overview</a> )
ATMP(s)	Advanced Therapy Medicinal Product(s) (i.e. gene, cell and tissue engineering products)
BA	Bioavailability
BE	Bioequivalence (see also Country codes: BE = Belgium)

<sup>1</sup> Acronyms are abbreviations that can be pronounced as a word (e.g. 'CAT') whereas initialisms are abbreviations for which each letter is pronounced separately (as in 'SME')



BEMA	Benchmarking of European Medicines Agencies (see <a href="#">Integrated quality management system</a> )
BCP	(EMA) Business Continuity Planning
BMWP	(EMA) Biosimilar Medicinal Products Working Party
B/R	Benefit/Risk (in B/R assessment, B/R balance, B/R profile...)
BWP	(EMA) Biologics Working Party
CAP(s)	Centrally Authorised Product(s)
CAPA plan	Corrective and preventive action plan
CAR-T cell	Chimeric antigen receptor T cell
<b>CAT</b>	(EMA) Committee for Advanced Therapies
CBMP	Cell-based Medicinal Product
CCDS	Company Core Data Sheet (see <a href="#">GVP annex I</a> )
CCI	Commercially Confidential Information
CCSI	Company Core Safety Information (see <a href="#">GVP annex I</a> )
CdT	Centre de Traduction (see <a href="#">Translation Centre for the bodies of the EU</a> )
CDx	Companion Diagnostics
CDP	(EMA) Clinical Data Publication (see <a href="#">Clinical data publication</a> )
CE mark	Conformité Européenne = European conformity mark (see <a href="#">Medical Devices</a> )
CECP	Clinical Evaluation Consultation Procedure (see <a href="#">Medical Devices</a> )
CEP(s)	Certificate(s) of Suitability to the monographs of the European Pharmacopoeia (see <a href="#">EDQM- Certification of suitability</a> )
<b>CHMP</b>	(EMA) Committee for Medicinal Products for Human Use ( <i>previously: CPMP</i> )
CI	Confidence interval
CI	Contraindication
CIOMS	Council for International Organizations of Medical Sciences
CMA	Conditional Marketing Authorisation
<b>CMDh</b>	Coordination Group for Mutual Recognition and Decentralised Procedures (human)
CMDS	Critical Medical Devices Shortage or System
CMS(s)	Concerned Member State(s)
CNSWP	(EMA) Central Nervous System Working Party (see <a href="#">CNSWP</a> )
<b>COMP</b>	(EMA) Committee for Orphan Medicinal Products
CP	Centralised Procedure (see <a href="#">Applying for EU marketing authorisation</a> )
CPAR	Consultation Procedure public Assessment Report (see <a href="#">CHMP opinions on consultation procedures</a> )
<i>CPMP</i>	<i>Committee for Proprietary Medicinal Products, former name of CHMP</i>
CRM	Customer Relationship Management
CRO	Contract Research Organisation
CSP(s)	Core Safety Profile(s)
CSR	Clinical Study Report
CTCG	Clinical Trial Coordination Group (see <a href="#">HMA CTCG</a> )
CTD	Common Technical Document – see eCTD
CTFG	Clinical Trial Facilitation Group (see <a href="#">HMA CTFG</a> )
CTIS	Clinical Trials Information System (see <a href="#">CTIS</a> )
CTR	Clinical Trial Regulation (see <a href="#">Clinical trials human medicines</a> )
CV	Curriculum vitae
<b>CVMP</b>	(EMA) Committee for Veterinary Medicinal Products
CVSWP	(EMA) Cardiovascular Working Party (see <a href="#">CVSWP</a> )

DARWIN EU®	Data Analysis and Real World Interrogation Network (see <a href="#">DARWIN EU</a> )
DCP	Decentralised Procedure (see <a href="#">Applying for EU marketing authorisation</a> )
DDCs	Drug-Device Combination(s)
DDPS(s)	Detailed Description of the Pharmacovigilance System(s)
DER	Drug Extract Ratio (see <a href="#">HMPC scientific guidelines</a> )
DG	Directorate-General (at the European Commission)
DG(s)	(EMA) Drafting Group(s) (see <a href="#">Working parties and domains</a> )
DHPC	Direct Healthcare Professional Communication (see <a href="#">GVP annex I</a> )
DIA	Drug Information Association
DIBD	Development International Birth Date (see <a href="#">GVP annex I</a> )
DLP	Data Lock Point
DoI	Declaration of Interests (see <a href="#">Handling competing interests</a> )
DSUR	Development Safety Update Report (see <a href="#">GVP annex I</a> )
DUS	Drug Utilisation Study
eAF	electronic Application Form
EC	European Commission ( <a href="http://ec.europa.eu/index_en.htm">http://ec.europa.eu/index_en.htm</a> )
ECDC	European Centre for Disease Prevention and Control ( <a href="https://www.ecdc.europa.eu/en">https://www.ecdc.europa.eu/en</a> )
ECHA	European Chemicals Agency ( <a href="https://echa.europa.eu/">https://echa.europa.eu/</a> )
eCTD	electronic Common Technical Document (see <a href="#">eSubmission website's section on eCTD</a> )
EDPS	European Data Protection Supervisor (see <a href="#">Data protection and privacy</a> )
EDQM	European Directorate for the Quality of Medicines (see <a href="#">EDQM of the Council of Europe</a> )
EEA	European Environment Agency ( <a href="https://www.eea.europa.eu/">https://www.eea.europa.eu/</a> )
EEA-EFTA states	European Economic Area – European Free Trade Association states
EFSA	European Food Safety Authority ( <a href="http://www.efsa.europa.eu">http://www.efsa.europa.eu</a> )
EHDS	European Health Data Space ( <a href="https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en">https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en</a> )
EMA/CAT-NB	Ad hoc European Medicines Agency/Committee for Advanced Therapies and Medical Devices Notified Body Collaboration Group – see <a href="#">EMA/CAT-NB</a>
EMCDDA	European Monitoring Centre for Drugs and Drug Addiction ( <a href="http://www.emcdda.europa.eu">http://www.emcdda.europa.eu</a> )
EMEA	<i>Old acronym for: European Medicines Agency; use: EMA</i>
EMR	Electronic Medical Records
EMRN	European Medicines Regulatory Network (see <a href="#">EMRN</a> )
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ( <a href="https://www.encepp.eu/">https://www.encepp.eu/</a> )
Enpr-EMA	European network of paediatric research at EMA (see <a href="#">Enpr-EMA</a> )
EP	European Parliament ( <a href="http://www.europarl.europa.eu/">http://www.europarl.europa.eu/</a> )
EPAR	European Public Assessment Report
e-PI	electronic Product Information
EPITT	European Pharmacovigilance Issues Tracking Tool
ERA	Environmental Risk Assessment
ERMS	European Risk Management Strategy (see <a href="#">ERMS</a> )
eRMR	electronic Reaction Monitoring Report
ESEC(s)	(EMA) European Specialised Expert Community(ies) (see <a href="#">Working parties and</a>

	<a href="#">domains</a> )
ESMP	European Shortages Monitoring Platform (see <a href="#">Availability of medicines</a> )
ETF	(EMA) Emergency Task Force (see <a href="#">ETF</a> )
EU	European Union
EU-ADR Project	Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge ( <i>formerly known as ALERT</i> )
EUDAMED	European database on medical devices (see <a href="#">EUDAMED</a> )
Eudra-	European Union Drug Regulating Authorities
EudraCT	European Union Drug Regulating Authorities Clinical Trials database: see <a href="#">EudraCT</a> and <a href="#">EU Clinical Trials Register</a>
EU-IN	(Joint HMA/EMA) EU Innovation Network (see <a href="#">EU-IN</a> )
EU-M4all	EU Medicines for all: see <a href="#">Medicines for use outside the European Union</a> ( <i>formerly known as 'Article 58 procedure'</i> )
EUnetHTA	European Network for Health Technology Assessment
EU-NTC	EU Network Training Centre (see <a href="#">EU-NTC</a> )
EU PAS Register	EU Post-Authorisation Study register
EURD list	List of EU Reference Dates and frequency of PSUR submission (see <a href="#">EURD list</a> )
EURORDIS	European Organisation for Rare Diseases ( <a href="http://www.eurordis.org/">http://www.eurordis.org/</a> )
<i>EUTCT</i>	<i>European Union Telematics Controlled Terms – has been replaced by RMS</i>
EU IVMAB	EU Immunisation and Vaccine Monitoring Board
EV	EudraVigilance (see <a href="#">EudraVigilance: electronic reporting</a> )
EV-EWG	EudraVigilance Expert Working Group (see <a href="#">EV-EWG</a> )
EVMPD	EudraVigilance Medicinal Products Dictionary
fAR	final Assessment Report
FDA	Food and Drug Administration (US) (see <a href="#">International agreements</a> )
FDC	Fixed Dose Combination
FDHA	Swiss Federal Department of Home Affairs (see <a href="#">International agreements</a> )
FMD	Falsified Medicines Directive (see <a href="#">Falsified medicines: overview</a> )
fvAR	final variation Assessment Report
FWG	(EMA) Formulation Working Group (see <a href="#">FWG</a> )
GACP	Good Agricultural and Collection Practice (see <a href="#">HMPC GACP guideline</a> )
GCG	(EMA) Guideline Consistency Group (see <a href="#">GCG</a> )
GCP	Good Clinical Practice (see <a href="#">GCP</a> )
GCP IWG	Good Clinical Practice Inspectors Working Group (see <a href="#">Compliance: overview</a> )
GDP	Good Distribution Practice (see <a href="#">GDP</a> )
GDPR	General Data Protection Regulation (see <a href="#">Workshop on GDPR and secondary use of data for medicines and public health purposes</a> )
GEG	(EMA) Geriatric Expert Group (see <a href="#">GEG</a> )
GLP	Good Laboratory Practice (see <a href="#">GLP</a> )
GMA	Global Marketing Authorisation
GMP	Good Manufacturing Practice (see <a href="#">GMP</a> )
GMDP IWG	Good Manufacturing Practice/Good Distribution Practice Inspectors Working Group (see <a href="#">Compliance: overview</a> )
GPAG	(EMA PRAC) Granularity and Periodicity Advisory Group
GSPR	General Safety and Performance Requirements (see <a href="#">Medical Devices</a> )
GTMP	Gene Therapy Medicinal Product
GVP	Good Pharmacovigilance Practices (see <a href="#">GVP</a> )

HAEMWP	(EMA) Haematology Working Party (see <a href="#">HAEMWP</a> )
HBD	Harmonised Birth Date
HC	Health Canada (see <a href="#">International agreements</a> )
HCP(s)	Healthcare Professional(s)
HCPWP	(EMA) Healthcare Professionals' Working Party (see <a href="#">HCPWP</a> )
HMA - HMA-Joint - HMA(h) - HMA(v)	Heads of Medicines Agencies ( <i>formerly: HoA</i> ) – see <a href="#">HMA</a> with three groups: HMA-Joint, HMA-Human and HMA-Veterinary
HMP	Herbal Medicinal Product (see <a href="#">EU herbal monographs</a> )
<b>HMPC</b>	(EMA) Committee on Herbal Medicinal Products
<i>HoA</i>	<i>was: Heads of Agencies, use: HMA</i>
HP	Herbal preparation (see <a href="#">EU herbal monographs</a> ) <i>equivalent to 'Herbal drug preparation' in Ph. Eur. monographs</i>
HR	Hazard Ratio
HS	Herbal substance (see <a href="#">EU herbal monographs</a> ) <i>equivalent to 'Herbal drug' in Ph. Eur. monographs</i>
HTA	Health Technology Assessment
HTABs	Health Technology Assessment Bodies (see <a href="#">HTA Bodies</a> )
IBD	International Birth Date (see <a href="#">GVP</a> annex I)
ICH	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
ICMRA	International Coalition of Medicines Regulatory Authorities (see <a href="#">ICMRA</a> )
ICSR(s)	Individual Case Safety Report(s) (see <a href="#">GVP</a> annex I)
IGDRP	International Generic Drug Regulators Programme
IDWP	(EMA) Infectious Diseases Working Party (see <a href="#">IDWP</a> )
im	intramuscular
IMP	(EU Regulatory Network) Incident Management Plan (see <a href="#">IMP</a> )
INN	International Non-proprietary Name (see <a href="#">WHO/INN</a> )
IPs	Interested Parties
IPRP	International Pharmaceutical Regulators Programme (see <a href="#">IPRP</a> )
IR	Inspection Report
IRCH	International Regulatory Cooperation for Herbal Medicines (under WHO)
IIR	Integrated Inspection Report
IRIS	<i>Not an abbreviation. Refers to an Agency's regulatory &amp; scientific information management platform between EMA and stakeholders (NCAs, industry)</i>
IRN	(EU Regulatory Network) Incident Review Network (see <a href="#">IMP</a> )
ISO IDMP	Internal Organization for Standardization for the Identification of Medicinal Products (see <a href="#">ISO IDMP standards</a> ) – implementation through the following EMA services: - OMS = Organisation Management Service - PMS = Product Management Service - RMS = Referentials Management Service - SMS = Substance Management Service
ITF	(EMA) Innovation Task Force (see <a href="#">Innovation in medicines</a> )
ITT	Intention-To-Treat (analysis)
iv	intravenous

IVD	In vitro Diagnostics
IVDR	In vitro Diagnostics Regulation (see <a href="#">Medical Devices</a> )
JAP	(HMA/EMA) Joint Audit Plan
Joint 3Rs WP	(EMA) Joint CHMP/CVMP 3Rs Replacement, Reduction and Refinement Working Party (see <a href="#">3Rs principles</a> )
KPI	Key Performance Indicator
LE	List entry (see <a href="#">EU herbal monographs and list entries</a> )
LoOI	List of Outstanding Issues
LoQ	List of Questions
LTT	Lines to take [ <i>internal EMA document usually not for publication</i> ]
MA	Marketing Authorisation
MAA	Marketing Authorisation Application
MAH	Marketing Authorisation Holder
MB	(EMA) Management Board
MD	Medical Device
MDCG	Medical Device Coordination Group
MDR	Medical Devices Regulation
MDSSG	Medical Devices Shortages Steering Group
MedDRA	Medical Dictionary for Regulatory Activities – organised in a hierarchical structure characterised by different levels: - SOC = System Organ Class - HLGT = High Level Group Term - HLT = High Level Term - PT = Preferred Term - LLT = Lowest Level Term
MLWP	Monographs and List entries Working Party (former HMPC working party)
MNAT	Multinational Assessment Team (see <a href="#">Multinational assessment team concept</a> )
MO	Major Objection
MoU	Memorandum of Understanding
MR	Mutual Recognition
MRA	Mutual Recognition Agreement (see <a href="#">MRA</a> )
MRP	Mutual Recognition Procedure (see <a href="#">Applying for EU marketing authorisation</a> )
MS(s)	Member State(s) of the European Union
MSSG	Medicines Shortages Steering Group (see <a href="#">MSSG</a> )
MWP	(EMA) Methodology Working Party (see <a href="#">MWP</a> )
NAS	New Active Substance
NAP(s)	Nationally Authorised Product(s)
NcWP	(EMA) Non-clinical Working Party (see <a href="#">NcWP</a> )
NCA(s)	National Competent Authority(ies)
NfG	Note for Guidance
NRG	(EMA) [Invented] Name Review Group (see <a href="#">NRG</a> )
NtA	Notice to Applicants (see <a href="#">Eudralex – Volume 2</a> )
NUI	Non-Urgent Information (see also RA/NUI System)
OD	Orphan Designation (see <a href="#">Orphan designation: Overview</a> )
OE	Oral Explanation
OEG(s)	(EMA) Operational Expert Group(s) (see <a href="#">Working parties and domains</a> ) - BOEG = Biostatistics Operational Expert Group

	- MSOEG = Modelling and Simulation Operational Expert Group - RWDOEG = Real World Data Operational Expert Group
OMCL(s)	Official Medicines Control Laboratory(ies) ( <a href="https://www.edqm.eu/en/omcl-background-and-mission">https://www.edqm.eu/en/omcl-background-and-mission</a> )
OMS	see ISO IDMP
ONCWP	(EMA) Oncology Working Party (see <a href="#">ONCWP</a> )
OPEN initiative	Opening our Procedures at EMA to Non-EU authorities - see <a href="#">OPEN Pilot: one-year review and recommendations</a>
ORGAM	Organisational Matters (see PROM; see also <a href="#">HMPC</a> )
OTC	Over-the-counter
PA	Protocol Assistance (see <a href="#">Scientific advice and protocol assistance</a> )
PaedPAR	Paediatric Public Assessment Report
PAES	Post-Authorisation Efficacy Study (see <a href="#">PAES Q&amp;A</a> )
PAM(s)	Post Authorisation Measure(s) categorised as follows in EMA's product and procedure tracking database – see <a href="#">PAMs Q&amp;A</a> ANX = Annex II condition LEG = Legally Binding Measure MEA = Additional PhV activity in the RMP SOB = Specific Obligation REC = Recommendation
pAR	preliminary Assessment Report
PASS	Post-Authorisation Safety Study (see <a href="#">GVP</a> annex I)
PBRER	Periodic Benefit-Risk Evaluation Report
PCWP	(EMA) Patients' and Consumers' Working Party (see <a href="#">PCWP</a> )
PD	Pharmacodynamic(s)
PD	(EMA) Parallel Distribution (see <a href="#">Parallel distribution</a> )
PdAR	Paediatric Assessment Report
<b>PDCO</b>	(EMA) Paediatric Committee
PECP	Performance Evaluation Consultation Procedure (see <a href="#">Medical Devices</a> )
PEM (study)	Prescription-Event Monitoring (study)
PHE	Public Health Emergency
Ph.Eur.	European Pharmacopoeia ( <a href="https://www.edqm.eu/en/european-pharmacopoeia">https://www.edqm.eu/en/european-pharmacopoeia</a> )
PhV	Pharmacovigilance
PhV IWG	Pharmacovigilance Inspectors Working Group (see <a href="#">Compliance: overview</a> )
<i>PhVWP</i>	<i>Pharmacovigilance Working Party (working party that preceded the PRAC)</i>
PI	Product Information (see <a href="#">Product Information requirements</a> )
PIC/S	Pharmaceutical Inspection Co-operation Scheme (see <a href="#">PIC/S</a> )
PIL	Patient Information Leaflet
PIP(s)	Paediatric Investigation Plan(s) (see <a href="#">PIPs</a> )
PK	Pharmacokinetic(s)
PL	Package Leaflet
PL	(EMA) Product Lead
PLD	Patient Level Data
PMDA	Pharmaceuticals and Medical Devices Agency (Japan) (see <a href="#">International agreements</a> )
PMF	Plasma Master File (see <a href="#">PMF certification</a> )
PMS	Post-Marketing Surveillance (see also under ISO IDMP)

POM	Prescription-only Medicine
PP	Per Protocol (analysis)
PPP	Pregnancy Prevention Programme
PRA	Preliminary Risk Analysis (see <a href="#">IMP</a> )
<b>PRAC</b>	(EMA) Pharmacovigilance Risk Assessment Committee
PRIME	(EMA) Priority Medicines scheme (see <a href="#">PRIME</a> )
PROM	Preparatory and Organisational Matters (see <a href="#">CHMP</a> – formerly known as ORGAM)
PRR	Proportional Reporting Ratio
PSA	Parallel Scientific Advice
PSMF	Pharmacovigilance System Master File (see <a href="#">GVP</a> annex I)
PSUFU	PSUSA Follow-Up
PSUR	Periodic Safety Update Report (see <a href="#">GVP</a> annex I)
PSUSA	PSUR Single Assessment
PUMA	Paediatric Use Marketing Authorisation (see <a href="#">PUMA</a> )
QIG	(EMA) Quality Innovation Group (see <a href="#">QIG</a> )
QoL	Quality of Life
QP	Qualified Person
QPPV	Qualified Person for Pharmacovigilance
QRD-WG	(EMA) Working Group on Quality Review of Documents (see <a href="#">QRD</a> )
QWP	(EMA) Joint CHMP/CVMP Quality Working Party (see <a href="#">QWP</a> )
RA	Rapid Alert – see also RA/NUI System
Raav	recombinant adeno-associated viral vector
RadDG	(EMA) Radiopharmaceuticals Drafting Group (see <a href="#">RadDG</a> )
RA/NUI System	Rapid Alert/Non-Urgent Information System
RCT(s)	Randomised Controlled Trial(s)
R&D	Research and Development
REA	Relative Effectiveness Assessment
REMS	Risk Evaluation & Mitigation Strategies
RFI	(EMA) Request for Information
RIWP	(EMA) Rheumatology/Immunology Working Party (see <a href="#">RIWP</a> )
RMAT	Regenerative Medicine Advanced Therapy
RMM(s)	Risk Minimisation Measure(s)
RMP or RefMP	Reference Medicinal Product
RMP	Risk Management Plan (see <a href="#">GVP</a> annex I)
RMR	Reaction Monitoring Report
RMS or RefMS	Reference Member State (see also 'RMS' under ISO IDMP)
ROG	Regulatory Optimisation Group (see <a href="#">HMA ROG</a> )
RPCs	Regional Pharmacovigilance Centres
RPI	Research Product Identifier (see <a href="#">Requesting SA or PA from EMA</a> )
RRR	Relative Risk Reduction
RSI	Request for Supplementary Information
RSS	Regulatory Science Strategy (see <a href="#">RSS</a> )
RUP	Repeat Use Procedure (see <a href="#">CMDh MRP/RUP</a> )
RWD	Real World Data
RWE	Real World Evidence
SA	Scientific Advice
SAE	Serious Adverse Event



SAG(s)	(EMA) Scientific Advisory Group(s)
SAP	Statistical Analysis Plan
SAWP	(EMA) Scientific Advice Working Party (see <a href="#">SAWP</a> )
SB	Significant Benefit
SBP(s)	Similar Biotherapeutic Product(s) (WHO term for biosimilars)
sc	subcutaneous
SFDA	State Food and Drug Authority (China) (see <a href="#">International agreements</a> )
SmAR	Summary Assessment Report
SMEs	Small and Medium-sized Enterprises (see <a href="#">Support to SMEs</a> )
SmPAR	Summary Pharmacovigilance Assessment Report
SmPC	Summary of Product Characteristics (see <a href="#">How to prepare and review a SmPC</a> )
SMQs	Standardised MedDRA Queries
SMS	See ISO IDMP
SNSA	Simultaneous National Scientific Advice (see <a href="#">HMA/EMA EU-IN</a> )
SoC	Standard of care
SOC	System Organ Class – see MedDRA
SOH	Scientific Opinion Holder (related to <a href="#">EU-M4all</a> )
SOP	Standard Operating Procedure
SPC	Supplementary Protection Certificate
SPOC	Single Point of Contact
EO-SPOC	(EMA) Economic Operators Single Point of Contact
SPOC WP	(EMA) Medicines Shortages Single Point of Contact Working Party (see <a href="#">SPOC WP</a> )
MD-SPOC WP	(EMA) Medical Device Shortages Single Point of Contact Working Party
SPOR	Substance, product, organisation and referential (see <a href="#">SPOR master data</a> )
SRLM	Strategic Review & Learning Meeting
SSR	Summary Safety Reports
SUSAR	Suspected Unexpected Serious Adverse Reactions
Swissmedic	Swiss Agency for Therapeutic Products (see <a href="#">International agreements</a> )
TCM	Traditional Chinese Medicine
tDGs	(EMA) temporary Drafting Groups (see <a href="#">Working parties and domains</a> )
TDD	Total Daily Dose
TGA	Therapeutic Goods Administration (Australia) (see <a href="#">International agreements</a> )
ToC	Table of Conclusions
ToD	Table of Decisions
THMP	Traditional Herbal Medicinal Product (see <a href="#">EU herbal monographs</a> )
TU	Traditional Use (see <a href="#">EU herbal monographs</a> )
TUR	Traditional Use Registration (see <a href="#">EU herbal monographs</a> )
UDI	Unique Device Identifier (see <a href="#">Medical Devices</a> )
UI	Unique Identifier (see <a href="#">Falsified medicines: overview</a> )
UMN	Unmet Medical Need
USR	Urgent Safety Restriction
VarWP	Working Party on Variation Regulation (see <a href="#">Variations for human medicines</a> )
VMP	(ECDC/EMA) Vaccine Monitoring Platform (see <a href="#">Vaccine Monitoring Platform</a> )
VWP	(EMA) Vaccines Working Party (see <a href="#">VWP</a> )
WEU	Well-established use
WG(s)	Working Group(s)
WHO	World Health Organization

WHO-UMC	WHO-Uppsala Monitoring Centre
WP(s)	Working party(ies) (see <a href="#">Working parties and domains</a> )
WS	Work Sharing

## Country codes of EU/EEA Countries<sup>2</sup>

Country (short name in English)	Country Code	Agency	Acronym
Austria	AT	Austrian Agency for Health and Food Safety	AGES
Belgium	BE	Federal Agency for Medicines and Health Products	FAMHP
Bulgaria	BG	Bulgarian Drug Agency	BDA
Croatia	HR	Agency for medicinal products and medical devices of Croatia	HALMED
Cyprus	CY	Ministry of Health -Pharmaceutical Services	MOH
Czech Republic	CZ	State Institute for Drug Control	SUKL
Denmark	DK	Danish Medicines Agency	DKMA
Estonia	EE	State Agency of Medicines	
Finland	FI	Finnish Medicines Agency	FIMEA
France	FR	National Agency for the Safety of Medicines and Health Products	ANSM
Germany	DE	Federal Institute for Drugs and Medical Devices	BfArM
Greece	GR (ISO) EL <sup>2</sup>	National Organization for Medicines	EOF
Hungary	HU	National Institute of Pharmacy and Nutrition	OGYI
Iceland	IS	Icelandic Medicines Agency	IMA
Italy	IT	Italian Medicines Agency	AIFA
Ireland	IE	Health Products Regulatory Authority	HPRA
Latvia	LV	State Agency of Medicines	ZVA
Liechtenstein	LI	Office of Health/ Department of Pharmaceuticals	
Lithuania	LT	State Medicines Control Agency	VVKT
Luxembourg	LU	Ministry of Health	MS
Malta	MT	Malta Medicines Authority	MMA
Netherlands	NL	Medicines Evaluation Board	CBG-MEB
Norway	NO	Norwegian Medicines Agency	NOMA

<sup>2</sup> Sources: <http://publications.europa.eu/code/en/en-370100.htm> and <http://www.iso.ch/iso/en/prods-services/iso3166ma/02iso-3166-code-lists/list-en1.html>;  
<https://ec.europa.eu/environment/enlarg/candidates.htm#:~:text=Albania%2C%20Moldova%2C%20the%20Republic%20of,possible%20request%20for%20transition%20periods.>

Poland	PL	Office for Registration of Medicinal Products, Medical Devices and Biocidal Products	URPL
Portugal	PT	National Authority of Medicines and Health Products	INFARMED
Romania	RO	National Agency for Medicines and Medical Devices	ANM
Slovakia	SK	State Institute for Drug Control	SUKL
Slovenia	SI	Agency for Medicinal Products and Medical Devices of the Republic of Slovenia	JAZMP
Spain	ES	Spanish Agency of Medicines and Medical Devices	AEMPS
Sweden	SE	Medical Products Agency	MPA

### Country Codes of Accession/Candidate Countries<sup>2</sup>

Country	Country Code
Albania	AL
Moldova	MD
The Republic of North Macedonia	MK
Montenegro	ME
Serbia	RS
Turkey	TR
Ukraine	UA

### Country Codes of Other European Countries<sup>2</sup>

Country	ISO Country Code
Andorra	AD
Armenia	AM
Azerbaijan	AZ
Belarus	BY
Bosnia and Herzegovina	BA
Georgia	GE
Holy See (Vatican City State)	VA
Monaco	MC
Russia	RU
San Marino	SM
Switzerland	CH
Vatican City State	See <i>Holy See</i>

### Other Country Codes<sup>2</sup>

Country	ISO Country Code
Australia	AU
Canada	CA

China	CN
Japan	JP
New Zealand	NZ
United States (of America)	US(A)